Journal
BONE MARROW TRANSPLANTATION
Volume 42, Issue 6, Pages 413-420Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2008.180
Keywords
myeloma; SCT; progression; survival
Categories
Funding
- Hematologic Malignancies Program
- Mayo Clinic CR20 program
- ASCO Young Investigator Award
- Amgen Oncology Institute Junior Faculty Award
Ask authors/readers for more resources
Auto-SCT is an effective therapy for patients with multiple myeloma (MM), but nearly a fifth of these patients relapse within a year of auto-SCT. We studied 494 patients, undergoing auto-SCT within 12 months of diagnosis of MM. Patients were divided into two groups: early relapse (relapse p12 months from auto-SCT) and late relapse (either relapsed 412 months after auto-SCT or disease free at the last follow up). One hundred twenty patients (24%) were in the early relapse and 374 (76%) were in the late-relapse groups. The early relapse group had a significantly shorter median overall survival (OS) from diagnosis (26.6 vs 90.7 months; P<0.001) and from auto-SCT (20.1 vs 82.5 months; P<0.001). Among the 345 patients who have relapsed after auto-SCT, median OS from relapse was 10.8 months in the early relapse group compared to 41.8 months for the rest (P<0.001) and was longer with increasing duration of response to the SCT. In multivariate analyses, labeling index >= 1% at transplant, greater than one treatment regimen prior to auto-SCT, and failure to achieve a complete response were predictive of early relapse. Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available